The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| KPRX | -44.06% | -99.92% | -75.78% | -100% |
| S&P | +12.16% | +74.91% | +11.82% | +224% |
Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$38.24K | -168.7% |
| Gross Margin | 10.62% | 0.0% |
| Market Cap | $9.55M | -12.2% |
| Market Cap / Employee | $795.42K | 0.0% |
| Employees | 12 | 0.0% |
| Net Income | $26.81K | 100.8% |
| EBITDA | -$2,477.24K | 7.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $5.51M | -2.3% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $248.24K | 533.4% |
| Short Term Debt | $155.93K | 366.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -24.99% | -45.4% |
| Return On Invested Capital | -94.03% | 24.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1,273.52K | -238.4% |
| Operating Free Cash Flow | -$1,273.09K | -238.4% |
| Metric | Q4 2024 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 4.67 | - | |||
| Price to Book | 0.33 | 0.35 | 0.36 | 0.43 | 31.36% |
| Price to Sales | 1.09 | 0.96 | 0.62 | 634.66 | 40965.00% |
| Price to Tangible Book Value | 0.42 | 0.47 | 0.51 | 0.62 | 38.18% |
| Price to Free Cash Flow TTM | 3.46 | 3.70 | 1.89 | 1.16 | - |
| Enterprise Value to EBITDA | 3.10 | 5.53 | 3.93 | 2.76 | -45.20% |
| Free Cash Flow Yield | 28.9% | 27.0% | 53.0% | 86.4% | - |
| Return on Equity | 22.6% | -41.1% | -43.4% | -32.6% | -211.93% |
| Total Debt | $57.17K | $159.02K | $430.41K | $404.17K | 456.42% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
